Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 15, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 16, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000785161-26-000004
Filed / recorded
Jan 16, 2026, 9:18 PM UTC
Added to OQRO
Oct 6, 2026, 7:37 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Encompass Health Corp
Issuer CIK
785161
Ticker
EHC
Reporting person
Edward M Iii Christie
Relationship
Director
Security
Encompass Health Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 15, 2026
Transaction code
A
Shares / units
269
Price per share
$102.82
Acquired / disposed
Acquired (A)
Shares owned after
7,182
Ownership form
Direct
Amendment
No
Footnotes from the filing
The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.
This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.82 to $102.90, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.